Single User License
INR 102555
Site License
INR 205110
Corporate User License
INR 307665

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Emergent BioSolutions Inc.-Product Pipeline Review-2015

Emergent BioSolutions Inc.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Emergent BioSolutions Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Emergent BioSolutions Inc.-Product Pipeline Review-2015', provides an overview of the Emergent BioSolutions Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Emergent BioSolutions Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Emergent BioSolutions Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Emergent BioSolutions Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Emergent BioSolutions Inc.'s pipeline products

Reasons To Buy

Evaluate Emergent BioSolutions Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Emergent BioSolutions Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Emergent BioSolutions Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Emergent BioSolutions Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Emergent BioSolutions Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Emergent BioSolutions Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Emergent BioSolutions Inc. Snapshot 6

Emergent BioSolutions Inc. Overview 6

Key Information 6

Key Facts 6

Emergent BioSolutions Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Emergent BioSolutions Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Emergent BioSolutions Inc.-Pipeline Products Glance 14

Emergent BioSolutions Inc.-Late Stage Pipeline Products 14

Filing rejected/Withdrawn Products/Combination Treatment Modalities 14

Emergent BioSolutions Inc.-Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Emergent BioSolutions Inc.-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Emergent BioSolutions Inc.-Drug Profiles 19

coagulation factor IX (recombinant) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

AV-7909 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

otlertuzumab 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

PreviThrax 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

AVP-21D9 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ES-414 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

antihemophilic factor (recombinant) 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ES-210 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ES-301 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ES-306 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

EV-035 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

GC-072 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

MVA-RSV 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

MVAH-5HA 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Recombinant Protein Cytotoxic to Cells Expressing CD19 and CD3 for Cancer 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Recombinant Protein to Target HER-2 and CD3 for Cancer 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Recombinant Protein to Target RON and CD3 for Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Vaccines for Undisclosed Indication 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Emergent BioSolutions Inc.-Pipeline Analysis 42

Emergent BioSolutions Inc.-Pipeline Products by Target 42

Emergent BioSolutions Inc.-Pipeline Products by Route of Administration 44

Emergent BioSolutions Inc.-Pipeline Products by Molecule Type 45

Emergent BioSolutions Inc.-Pipeline Products by Mechanism of Action 46

Emergent BioSolutions Inc.-Recent Pipeline Updates 48

Emergent BioSolutions Inc.-Dormant Projects 56

Emergent BioSolutions Inc.-Discontinued Pipeline Products 57

Discontinued Pipeline Product Profiles 57

Anthrivig 57

Immune Globulin 57

Leucotropin 57

PEP-35 57

TST-10088 57

Emergent BioSolutions Inc.-Company Statement 58

Emergent BioSolutions Inc.-Locations And Subsidiaries 61

Head Office 61

Other Locations & Subsidiaries 61

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

Emergent BioSolutions Inc., Key Information 6

Emergent BioSolutions Inc., Key Facts 6

Emergent BioSolutions Inc.-Pipeline by Indication, 2015 8

Emergent BioSolutions Inc.-Pipeline by Stage of Development, 2015 10

Emergent BioSolutions Inc.-Monotherapy Products in Pipeline, 2015 11

Emergent BioSolutions Inc.-Partnered Products in Pipeline, 2015 12

Emergent BioSolutions Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

Emergent BioSolutions Inc.-Filing rejected/Withdrawn, 2015 14

Emergent BioSolutions Inc.-Phase II, 2015 15

Emergent BioSolutions Inc.-Phase I, 2015 16

Emergent BioSolutions Inc.-Preclinical, 2015 17

Emergent BioSolutions Inc.-Discovery, 2015 18

Emergent BioSolutions Inc.-Pipeline by Target, 2015 43

Emergent BioSolutions Inc.-Pipeline by Route of Administration, 2015 44

Emergent BioSolutions Inc.-Pipeline by Molecule Type, 2015 45

Emergent BioSolutions Inc.-Pipeline Products by Mechanism of Action, 2015 47

Emergent BioSolutions Inc.-Recent Pipeline Updates, 2015 48

Emergent BioSolutions Inc.-Dormant Developmental Projects,2015 56

Emergent BioSolutions Inc.-Discontinued Pipeline Products, 2015 57

Emergent BioSolutions Inc., Other Locations 61

Emergent BioSolutions Inc., Subsidiaries 61

List of Figures

Emergent BioSolutions Inc.-Pipeline by Top 10 Indication, 2015 8

Emergent BioSolutions Inc.-Pipeline by Stage of Development, 2015 10

Emergent BioSolutions Inc.-Monotherapy Products in Pipeline, 2015 11

Emergent BioSolutions Inc.-Pipeline by Top 10 Target, 2015 42

Emergent BioSolutions Inc.-Pipeline by Top 10 Route of Administration, 2015 44

Emergent BioSolutions Inc.-Pipeline by Top 10 Molecule Type, 2015 45

Emergent BioSolutions Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Emergent BioSolutions Inc.; Emergent BioSolutions Inc. - Key Therapeutics; Emergent BioSolutions Inc. - Pipeline Overview and Promising Molecules; Emergent BioSolutions Inc. - News; Emergent BioSolutions Inc. - Latest Updates; Emergent BioSolutions Inc. - Pipeline; Emergent BioSolutions Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com